PROTAC ERα Degrader-8 is a chemical compound designed as a targeted protein degradation agent, specifically aimed at the estrogen receptor alpha (ERα). This compound belongs to a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which harness the cellular ubiquitin-proteasome system to selectively degrade specific proteins. The structure of PROTAC ERα Degrader-8 typically includes a ligand that binds to ERα and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein. This mechanism allows for the modulation of protein levels in a highly specific manner, making it a valuable tool in research and potential therapeutic applications, particularly in hormone-dependent cancers. The compound's efficacy and selectivity are influenced by its chemical structure, which can be optimized for improved performance. As a relatively novel approach in drug development, PROTACs like ERα Degrader-8 represent a promising strategy for overcoming challenges associated with traditional small molecule inhibitors.

PROTAC ERα Degrader-8

3025533-68-7: PROTAC ERα Degrader-8 is a chemical compound designed as a targeted protein degradation agent, specifically aimed at the estrogen receptor alpha (ERα). This compound belongs to a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which harness the cellular ubiquitin-proteasome system to selectively degrade specific proteins. The structure of PROTAC ERα Degrader-8 typically includes a ligand that binds to ERα and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein. This mechanism allows for the modulation of protein levels in a highly specific manner, making it a valuable tool in research and potential therapeutic applications, particularly in hormone-dependent cancers. The compound's efficacy and selectivity are influenced by its chemical structure, which can be optimized for improved performance. As a relatively novel approach in drug development, PROTACs like ERα Degrader-8 represent a promising strategy for overcoming challenges associated with traditional small molecule inhibitors.

<p>PROTAC ERα Degrader-8 (compound ii-56), a highly potent degrader of Erα, achieves a DC50 of just 0.000006 μM in MCF7 cells [1].</p>

CAS 3025533-68-7

PROTAC ERα Degrader-8

PROTAC ERα Degrader-8

Ref: TM-T87265